Navigation Links
Serendipity points to new potential target and therapy for melanoma

A University of Colorado Cancer Center study in this month's edition of the Journal of Investigative Dermatology describes a new target and potential treatment for melanoma, the most dangerous form of skin cancer. MicroRNA can decide which genes in a cell's DNA are expressed and which stay silent. Melanoma tends to lack microRNA-26a, which makes the gene SODD go silent.

"It's a double negative," says Yiqun Shellman, PhD, investigator at the CU Cancer Center, associate professor at the CU School of Medicine, and the study's co-senior author. "miR-26a works to stop the growth of cancer. You turn off this thing that should stop growth, and you have growth."

When Shellman, David Norris and colleagues reintroduced microRNA-26a to melanoma cell lines that lacked it, they saw a marked decrease in cancer cell survival. MicroRNA-26a killed melanoma cells while leaving healthy cells unharmed.

In fact, the discovery started back a couple steps. First the group compared microRNA expression in healthy cells to that of microRNA expression in melanoma cells. "We hoped the difference between microRNA expression in healthy and melanoma cells would show which ones were contributing to tumorgenesis," Shellman says.

The microRNA most consistently different between healthy and cancerous cells was 26a. The discovery of how it works and what exactly it does was serendipitous. "We started by testing the effect of microRNA-26a on known gene targets to see if it was effecting the expression of logical, cancer-causing pathways, but none of them seemed affected in melanoma," Shellman says. "We were working with the SODD gene in an unrelated project, and SODD has a putative but not high-scored binding site for miR-26a, and thought, why not test it? Sure enough, it turned out to be the target microRNA-26a downregulates this gene."

Shellman hopes this robust finding in cell cultures will help pave the way for future work with microRNA-26a as a therapeutic target in animal models and eventually a human trial.

"The first step is to further pinpoint the genetic signatures of the patients likely to benefit from microRNA-26a replacement therapy," Shellman says, noting that only some and not all melanoma cells were killed by miRNA replacement. "Maybe it's simply the downregulation of microRNA-26a itself, or maybe we can use SODD expression as the biomarker," Shellman says.

Once Shellman and colleagues discover the characteristics of a melanoma susceptible to microRNA-26a treatment, they hope funding will allow the lab to follow the promising therapy up the evolution from cells to humans.


Contact: Garth Sundem
University of Colorado Denver

Related biology news :

1. Research pinpoints key gene for regenerating cells after heart attack
2. Protein injection points to muscular dystrophy treatment
3. University of Maryland School of Medicine, NIH study pinpoints brain areas role in learning
4. New study to examine ecological tipping points in hopes of preventing them
5. Remarkable enzyme points the way to reducing nitric acid use in industry
6. U OF A expert pinpoints nutrient behind fresh water algae blooms
7. Under the right conditions, peptide blocks HIV infection at multiple points along the way
8. Study points to causes of high dolphin deaths in Gulf of Mexico
9. Conatus Pharmaceuticals Appoints Mark F. Morris as Head of Biostatistics
10. 3-V Biosciences Appoints Douglas I. Buckley, PhD, as Vice President of Biology
11. Computer model pinpoints prime materials for efficient carbon capture
Post Your Comments:
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... ) The integration will ... to access and transact across channels. Using this ...
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... DIEGO , June 27, 2016  Sequenom, Inc. ... committed to enabling healthier lives through the development of ... Court of the United States ... courts that the claims of Sequenom,s U.S. Patent No. ... patent eligibility criteria established by the Supreme Court,s Mayo ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... Parallel ... clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module ... circle with the physician and clinical trial team. , Using the CONSULT module, patients ...
(Date:6/27/2016)... Hill, N.C. (PRWEB) , ... June 27, 2016 ... ... U.S. commercial operations for Amgen, will join the faculty of the University ... serve as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a ...
(Date:6/27/2016)... Ginkgo Bioworks , a leading organism design company ... as one of the World Economic Forum,s Technology ... companies. Ginkgo Bioworks is engineering biology to manufacture ... the nutrition, health and consumer goods sectors. The ... Fortune 500 companies to design microbes for their ...
Breaking Biology Technology: